COMMUNIQUÉS West-GlobeNewswire

Allakos Presents Preclinical Data Highlighting Inhibition of MRGPRX2-Mediated Mast Cell Activation with AK006 at AAAAI 2024
26/02/2024
– Atopic dermatitis and prurigo nodularis skin lesions show evidence of MRGPRX2 mast cell activation and activated macrophages – – AK006 inhibited mast cell activation and reduced mast cell numbers in an MRGPRX2-induced [...]
Celldex Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update
26/02/2024
- Phase 3 CSU studies expected to initiate in summer 2024 - - Positive Phase 2 CSU 12 week data reported in late breaking oral presentation at AAAAI 2024; 52 week data to be reported in 2H 2024 - - Enrollment nearing [...]
BioCryst Reports Fourth Quarter and Full Year 2023 Financial Results and Upcoming Key Milestones
26/02/2024
—ORLADEYO net revenue of $90.9 million for Q4 2023 and $326.0 million for FY 2023 (+30 percent y-o-y) — —2024 ORLADEYO net revenue expected to be between $380-$400 million— —Company expects operating profit in 2024, [...]
Mesoblast Financial Results and Corporate Update Webcast
26/02/2024
NEW YORK, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, will host a webcast to discuss operational highlights and [...]
Transactions in connection with share buy-back program
26/02/2024
Company Announcement COPENHAGEN, Denmark; February 26, 2024 – Genmab A/S (Nasdaq: GMAB). On February 14, 2024, Genmab announced the initiation of a share buy-back program to honor our commitments under our Restricted [...]
Alvotech Accepts Offer for the Sale of Shares for a value of approximately USD 166 million at a Purchase price of USD 16.41 (ISK 2,250) per Share
26/02/2024
REYKJAVIK, Iceland, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced [...]
Alvotech Accepts Offer for the Sale of Shares for a value of approximately USD 166 million at a Purchase price of USD 16.41 (ISK 2,250) per Share
26/02/2024
Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that it has accepted an offer from investors (the “ [...]
Community Health Worker (CHW) Initiative Launched In New Hampshire
26/02/2024
North Country Health Consortium Works With Partners to Improve Health Outcomes In the State Littleton, NH, Feb. 26, 2024 (GLOBE NEWSWIRE) -- The state of New Hampshire has provided funding to North Country Health [...]
Zealand Pharma announces Boehringer Ingelheim survodutide Phase 2 trial shows 83% of adults treated achieved groundbreaking results in liver disease due to MASH, with significant improvements in fibrosis
26/02/2024
Company announcement - No. 8 / 2024 Zealand Pharma announces Boehringer Ingelheim survodutide Phase 2 trial shows 83% of adults treated achieved groundbreaking results in liver disease due to MASH, with significant [...]
Survodutide Phase II trial shows 83% of adults treated achieved groundbreaking results in liver disease due to MASH, with significant improvements in fibrosis
26/02/2024
Survodutide has potential to become best-in-class treatment for metabolic dysfunction-associated steatohepatitis (MASH)*, after meeting its primary and key secondary endpoint following 48 weeks of treatment versus [...]
IBA Notice of Full Year 2023 Results and Conference Call
26/02/2024
FY23 results meeting to take place as a hybrid event on Thursday, 21 March 2024 at 3pm CET Louvain-la-Neuve, Belgium, 26 February 2024 - IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle [...]
IBA : Publication des résultats annuels 2023 et conférence web
26/02/2024
La conférence sur les résultats annuels aura lieu le jeudi 21 mars 2024 à 15h00, heure de Bruxelles Louvain-la-Neuve, Belgique, le 26 février 2024 - IBA (Ion Beam Applications S.A.), le premier fournisseur mondial de [...]
argenx to Present at Upcoming Investor Conferences
26/02/2024
February 26, 2024 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that [...]
New England Journal of Medicine publishes Phase III data showing Xolair significantly reduced allergic reactions across multiple foods in people with food allergies
25/02/2024
Detailed results from the NIH-sponsored Phase III OUtMATCH study showed treatment with Xolair increased the amount of peanuts, tree nuts, egg, milk and wheat that people as young as 1 year consumed without an allergic [...]
Celldex Therapeutics Presents Positive 12 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria
24/02/2024
- Primary and secondary endpoints met with clinically meaningful and statistically significant decreases in urticaria disease activity across multiple dose groups - - Sustained activity with rapid onset within 2 weeks [...]
Press Release: Phase 2 results demonstrate rilzabrutinib rapidly reduced itch severity and significantly improved disease activity in adults with chronic spontaneous urticaria
24/02/2024
Phase 2 results demonstrate rilzabrutinib rapidly reduced itch severity and significantly improved disease activity in adults with chronic spontaneous urticaria Late-breaking data at 2024 AAAAI showed rilzabrutinib, an [...]
Communiqué : Résultats de phase II montrent que le rilzabrutinib permet de réduire rapidement la sévérité des démangeaisons causées par l’urticaire chronique spontanée et d’améliorer significativement l’activité de la maladie chez l’adulte
24/02/2024
Des résultats de phase II montrent que le rilzabrutinib permet de réduire rapidement la sévérité des démangeaisons causées par l’urticaire chronique spontanée et d’améliorer significativement l’activité de la maladie [...]
Tilray Medical salue le Bundestag allemand et l’adoption historique de la loi sur le cannabis à usage médicinal en Allemagne
24/02/2024
La nouvelle loi allemande sur le cannabis à usage médicinal (Medizinal-Cannabisgesetz – « MedCanG ») permet aux patients d’accéder plus facilement à ce produit COLOGNE, Allemagne et NEUMÜNSTER, Allemagne, 24 févr. 2024 [...]
Alvotech and Teva Announce U.S. Approval of SIMLANDI® (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free biosimilar to Humira®
24/02/2024
SIMLANDI is t he first citrate-free, high-concentration biosimilar to be designated interchangeable to Humira in the U.S . SIMLANDI is the first biosimilar approval under the strategic partnership between Alvotech and [...]

Pages